SF
GILD icon

Summit Financial’s Gilead Sciences GILD Stock Holding History

Summit Financial’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.93M Sell
31,121
-1,028
-3% -$135K 0.04% 412
2026
Q1 		$4.48M Buy
32,149
+1,777
+6% +$249K 0.06% 343
2025
Q4 		$3.73M Buy
30,372
+2,999
+11% +$364K 0.05% 327
2025
Q3 		$3.04M Buy
27,373
+2,567
+10% +$292K 0.05% 370
2025
Q2 		$2.75M Buy
24,806
+3,913
+19% +$416K 0.06% 248
2025
Q1 		$2.34M Buy
20,893
+1,459
+8% +$151K 0.07% 236
2024
Q4 		$1.8M Buy
19,434
+15,484
+392% +$1.39M 0.06% 229
2024
Q3 		$331K Buy
3,950
+87
+2% +$6.64K 0.01% 442
2024
Q2 		$265K Buy
+3,863
New +$258K 0.01% 438

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Summit Financial's GILD Position: Q2 2026 in Review

Summit Financial reduced its Gilead Sciences (GILD) stake by 3.2% in Q2 2026, selling an estimated $135K and leaving 31,121 shares worth $3.93M. The position accounts for 0.04% of the portfolio, ranked #412.

Summit Financial first reported a position in GILD in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.48M in Q1 2026. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Summit Financial held 31,121 shares of Gilead Sciences worth $3.93M as of Q2 2026.
  • Summit Financial sold 1,028 Gilead Sciences shares in Q2 2026, an estimated $135K.
  • Gilead Sciences made up 0.04% of Summit Financial's portfolio in Q2 2026, its #412 holding.
  • Summit Financial first reported a position in Gilead Sciences in Q2 2024 and has held it in 9 quarters since.
  • Summit Financial's Gilead Sciences position peaked at $4.48M in Q1 2026.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Summit Financial's 13F filing for Q2 2026, filed 12 Aug 2026.